Human Microbiome Project

North America Human Microbiome Market 2017-2019 & 2025 - Rapid Adoption of Metagenomics and Next-Generation Sequencing Techniques

Retrieved on: 
Tuesday, April 16, 2019
Branches of biology, Microbiology, Biology, Bacteriology, Environmental microbiology, Human Microbiome Project, Bacteria, Human microbiota, Microbiota, DNA sequencing, Pharmacomicrobiomics

The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017.

Key Points: 
  • The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017.
  • The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome and next-generation sequencing.
  • Large governmental research initiatives including the Human Microbiome Project in the U.S. have accelerated research on the human microbiome.
  • Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

North America's Human Microbiome Market to 2025: Rapid Adoption of Metagenomics & Next-Generation Sequencing Techniques - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 16, 2019
Health, Biotechnology, Branches of biology, Microbiology, Biology, Bacteriology, Environmental microbiology, Human Microbiome Project, Bacteria, Human microbiota, Microbiota, DNA sequencing, Pharmacomicrobiomics

The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017.

Key Points: 
  • The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017.
  • The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome and next-generation sequencing.
  • Large governmental research initiatives including the Human Microbiome Project in the U.S. have accelerated research on the human microbiome.
  • Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Europe's Human Microbiome Market to 2025 - Regional Analysis & Forecasts by Product, Disease, Application and Country - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2019
Health, Biotechnology, Pharmaceutical, Branches of biology, Microbiology, Bacteriology, Organisms, Environmental microbiology, Bacteria, Human microbiota, Microbiota, Human Microbiome Project, Pharmacomicrobiomics

The "Europe Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The Europe human microbiome market is expected to reach US$ 346.67 Mn in 2025 from US$ 72.34 Mn in 2017.
  • Human microbiome is an emerging field in the country and the developments are being conducted widely in the country.
  • Thus, considering and analyzing the above mentioned factors, the human microbiome market is likely to grow with a significant growth rate in the coming future.

uBiome Launches Research Partnership with University of Louisville Physicians to Investigate the Microbiome as a Predictor of Clinical Response to IBD Therapies

Retrieved on: 
Thursday, March 7, 2019
Branches of biology, Microbiology, Bacteriology, Biology, Environmental microbiology, Citizen science, Genetic genealogy, uBiome, Human microbiota, Microbiota, Inflammatory bowel disease, Human Microbiome Project

"We are proud to support Dr. Wuerth and Dr. Dryden's mission to uncover the associations of the microbiome in clinical response to therapies for IBD."

Key Points: 
  • "We are proud to support Dr. Wuerth and Dr. Dryden's mission to uncover the associations of the microbiome in clinical response to therapies for IBD."
  • If microbiota does in fact act as a predictor, microbiome testing could be performed prior to selecting a certain agent.
  • A sufferer of IBD himself, he founded the popular website IBDwatch.org to broadcast news and research pertaining to IBD to both physicians and patients.
  • Through its Clinical Research Initiative, uBiome provides microbiome research support in study design, planning, sample collection and sequencing, and bioinformatic analysis to researchers.

The State of the Microbiome, 2019: Key Opportunities & Challenges - ResearchAndMarkets.com

Retrieved on: 
Friday, February 22, 2019
Health, Biotechnology, Pharmaceutical, Branches of biology, Microbiology, Bacteriology, Organisms, Bacteria, Microbiota, Environmental microbiology, Human Microbiome Project

Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of Microbiome therapeutics.

Key Points: 
  • Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of Microbiome therapeutics.
  • Identifying the mechanism of action was indicated by 27% of respondents as the most challenging aspect of developing Microbiome therapeutics.
  • Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with developing, launching and manufacturing microbiome therapeutics.
  • Develop business strategies by understanding the challenges associated with identifying and meeting regulatory requirements for the approval of microbiome therapeutics.

Better Gut Health May Lessen Depression

Retrieved on: 
Wednesday, February 20, 2019
Branches of biology, Medical specialties, Bacteriology, Microbiology, Environmental microbiology, Digestive system, Firmicutes, Gut flora, Microbiota, Leaky gut syndrome, Human Microbiome Project, Dysbiosis

The kind of signals sent may depend on the type of bacteria in the gut microbiome.

Key Points: 
  • The kind of signals sent may depend on the type of bacteria in the gut microbiome.
  • "Researchers are now finding that mental health conditions like depression are also linked to the type and amount of specific bacteria in the microbiome--and that diet and exercise can impact microbial composition."
  • Numerous studies show that poor dietsbased on fatty, processed, andhigh-sugar foods produce a gut microbiome that is less diverseandinduces inflammationthat can lead to leaky gut syndrome, which makes us more prone to diseases.
  • Depression costs U.S. employers an estimated $100 billion each year, including $44 billion a year in lost productivity alone.

Biomillenia Launches Microbiome Culture Collection Service

Retrieved on: 
Friday, February 1, 2019
Technology, Software, Health, Biotechnology, Genetics, Medical devices, Pharmaceutical, Branches of biology, Microbiology, Bacteriology, Organisms, Environmental microbiology, Bacteria, Microbiota, Human microbiota, Isolation, Microorganism, Microbiological culture, Human Microbiome Project

Biomillenia, a company focused on restoring a robust and resilient microbiota, announced today the launch of its microbiome culture collection service.

Key Points: 
  • Biomillenia, a company focused on restoring a robust and resilient microbiota, announced today the launch of its microbiome culture collection service.
  • In addition to unbiased culture collection services, partners have the option to include phenotypic selection, effectively screening for novel bacterial strains with desired traits.
  • We are supporting companies in these sectors by providing access to our microbial culture collection services and state of the art microbe isolation and sequencing technologies, said Dirk Loeffert, Ph.D., CEO of Biomillenia.
  • If you are interested in discussing the microbiome culture collection service, please contact [email protected] .

ConsortiaTX Co-Founder Awarded $1.5 Million National Institutes of Health (NIH) Grant to Develop Innovations for Microbiome Studies for Food Allergies

Retrieved on: 
Monday, January 7, 2019
Other Consumer, Technology, Software, Health, Biotechnology, Clinical trials, Small business, Professional services, Children, Other Professional Services, Research, Other Science, Consumer, Family, Science, General Health, Microbiology, Bacteriology, Clinical pathology, Microscopy, Environmental microbiology, Bacteria, Microbiota, Pharmacomicrobiomics, Human Microbiome Project

ConsortiaTX, Inc. co-founder, Georg Gerber, M.D., Ph.D., has been awarded a 5-year, $1.5 million National Institutes of Health (NIH) grant to advance machine learning and software tools for longitudinal microbiome studies.

Key Points: 
  • ConsortiaTX, Inc. co-founder, Georg Gerber, M.D., Ph.D., has been awarded a 5-year, $1.5 million National Institutes of Health (NIH) grant to advance machine learning and software tools for longitudinal microbiome studies.
  • ConsortiaTX has been developing and commercializing microbial therapies to prevent and treat human disease and allergies since its launch about a year and half ago.
  • Working at his lab at Brigham and Womens Hospital in Boston, Dr. Gerber and his team will develop innovative approaches to enable analyses of longitudinal microbiome studies.
  • We will develop improved machine learning models of microbial dynamics and the effects of the microbiome on the human host over time.

Global Microbiome Therapeutics and Diagnostics Pipeline Analysis and Market Outlook to 2027 - Several Key Leading Pipeline Products will Pave the Way Forward for the Future

Retrieved on: 
Thursday, October 4, 2018
Microbiology, Bacteriology, Biology, Clinical pathology, Environmental microbiology, Bacteria, Microbiota, Human microbiota, Pharmacomicrobiomics, Human Microbiome Project

The "Microbiome Therapeutics and Diagnostics, 2nd Edition: Pipeline Analysis and Market Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiome Therapeutics and Diagnostics, 2nd Edition: Pipeline Analysis and Market Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Key questions answered by Microbiome Therapeutics & Diagnostics: Pipeline Analysis and Market Outlook includes:
    What is the aim of human microbiome R&D?
  • Several key leading pipeline products will pave the way forward for the future human microbiome market.
  • : Pipeline Analysis and Market Outlook will enable you to:
    2.1 What is the Human Microbiome?

Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

Retrieved on: 
Friday, August 3, 2018
Cedars-Sinai Medical Center, Cedars, Health, Human Microbiome Project

Under the terms of the agreement, the lab of world-renowned microbiome researcher Mark Pimentel, M.D., executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center, will focus on the discovery of new therapeutic treatments related to conditions of the gut microbiome.

Key Points: 
  • Under the terms of the agreement, the lab of world-renowned microbiome researcher Mark Pimentel, M.D., executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center, will focus on the discovery of new therapeutic treatments related to conditions of the gut microbiome.
  • Salix has the option to acquire any therapeutic invention discovered through the research.
  • Salix and Cedars-Sinai Medical Center are looking to begin research in the third quarter of 2018.
  • Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases.